The non-invasive diagnosis of human glioma could improve the quality of life of patients with this disease by allowing patients to be directly diagnosed or stratified for treatment without the need of an invasive brain biopsy. In Core B, the investigators propose to develop a novel clinical sample core to study extracellular RNA biomarkers for the diagnosis of human glioma tumors. In collaboration with the P01 project investigators, we will study EV proteins, nucleic acids, and physical characteristics as potential biomarkers for glioma diagnosis or progression. We will work with a consortium of institutions to provide rapid prospective collection of tumor tissue, CSF, and blood from glioma patients. In additon, the Core will provide biostatistical support to all Projects.
Core B- Bob S. Carter PI Project Narrative Human brain tumors are challenging to diagnose and treat. Tumors may be located in critical parts of the brain that provide important function such as language or movement. Brian biopsy in these regions carries risk to the patient. A non-invasive means of diagnosing brain tumors would improve the quality of life of patients with this disease by reducing the need for invasive diagnostic procedures. In this study, we will analyze extracellular vesicles that are released from brain tumors into blood or cerebrospinal fluid as a means of diagnosing or improving the treatment of brain tumors. If successful, this research will improve the quality of life of patients with brain tumors and will open new avenues of research to study how patients respond to brain tumor treatments.
Showing the most recent 10 out of 223 publications
